Commercializing Biotech and Medtech: Why Great Science Still Has to Be SoldStrong clinical data doesn’t sell itself. How biotech and medtech commercialization translates science for physicians, payers, and patients.

Most biotech and medtech teams building toward a launch have spent years earning the right to have the conversation. The trial read out. The device cleared. The data is genuinely strong.

And then the launch arrives, and the market doesn’t move as fast as the science deserves. The gap that opens there is rarely a science problem. It’s a translation problem, and it’s the one most companies underestimate until they’re inside it.

Why doesn’t strong clinical data sell a product on its own?

Because the data is never the message. It’s the raw material for three different messages.

In biotech and medtech, a single product gets evaluated by three audiences who will never read the clinical story the same way. A physician weighs it against how they already practice and whether it fits the realities of their day. A value analysis committee, or a payer, weighs it against a budget and every other priority competing for the same dollars. A patient weighs it against their own fear, their own life, and whatever they understood from an appointment that went by too fast.

Same science. Three decisions. The team that generated the data reads it fluently, and none of those three audiences does. That gap is where commercialization lives.

What does commercialization actually mean in life sciences?

It’s the work of making rigorous science legible to each person who decides its future, without losing what makes it rigorous.

That spans the full lifecycle, not just launch week. Market landscape and competitive intelligence, so you know what the product is really being compared against. Clinical data translation, so the evidence becomes a story a physician can act on and a patient can follow. Positioning and brand identity, so the product means something consistent across every audience. Customer engagement and, for devices, the economic and value case that a purchasing committee needs before a clinician ever gets to choose.

Done early, this work shapes the trial narrative, the field strategy, and the patient materials before any of them are locked. Done late, it becomes a scramble to explain a product that’s already in market.

Why is medtech commercialization different from pharma?

The decision structure is different, and the economic case carries more weight earlier.

A medical device often has to win a value analysis committee before it reaches wide clinical use. That means the clinical benefit and the economic argument have to travel together from the start. A compelling clinical story with no cost-and-value case attached stalls in exactly the room that controls adoption. Device commercialization also has to account for the people who use the product and the systems that pay for it as distinct audiences with distinct questions, often at the same time.

What makes biotech commercialization hard for emerging companies?

Usually it’s that the commercial infrastructure doesn’t exist yet, and the first launch sets the reputation the next one inherits.

An emerging biotech is often launching without an established brand, without field relationships, and without a house playbook to lean on. Everything gets built for the first time. That’s not a disadvantage if the right people are building it, but it raises the cost of getting positioning wrong, because there’s no equity in reserve to absorb a weak start.

When should commercialization work begin?

Earlier than most teams plan for. The questions that decide a launch, who the product is for, what it’s compared against, what each audience needs to believe, get more expensive to answer the closer you get to launch day. Answered early, they give every downstream decision something solid to build on.

The translation is the work

Great science earns the right to be heard. It doesn’t guarantee it will be. The companies whose launches land are the ones who treat the translation of their science with the same rigor they brought to generating it, across biotech, medtech, and device.

That’s the work we’re built for, and it’s the conversation we most like being in early.